Volume 7, Number 2—April 2001
4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections
State of the Art
Economic Impact of Antimicrobial Resistance
|Focus||Individual||Individual||Care group||Potential clients||Population|
|Outcome||Absence of disease||Absence of disease||Reduce cost of care||Product sales||Maximize health|
|Time frame||Short||Short||Short||Short, long||Long|
|Motivation||Professionalism||Personal well-being||Profit||Profit||Social good|
|Approach||Treatment||Treatment||Cost containment||Develop new drugs, maintain life of old drugs||Reduce forces leading to resistance|
aCordell RL, Solomon SL, Scott RD, McGowan JE Jr, unpub. data.
Correction: On July 2, 2001 the following correction was made to this article in the second sentence of paragraph 1. The word "billion" replaced "million" in the phrase "...U.S.$4 to $5 million."